hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06380894, orgStudyIdInfo id: 2020/2239, briefTitle: Virtual Reality Cognitive Training for Mild Cognitive Impairment, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-01-27, primaryCompletionDateStruct date: 2022-09-30, completionDateStruct date: 2023-01-31, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Changi General Hospital, class: OTHER, descriptionModule briefSummary: This study aims to assess the feasibility and efficacy of a 10-weekly multi-domain VRCT program on the cognitive function (i.e. attention, memory, and executive functioning) of older adults with MCI., conditionsModule conditions: Mild Cognitive Impairment, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ACTUAL, armsInterventionsModule interventions name: Virtual Reality Cognitive Training, interventions name: Active Control, outcomesModule primaryOutcomes measure: Change from Baseline in Memory Performance on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) subtests at Week 11, primaryOutcomes measure: Change from Baseline in Attention Performance on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) subtest at Week 11, primaryOutcomes measure: Change from Baseline in Attention Performance on the Colour Trails Test 1 at Week 11, primaryOutcomes measure: Change from Baseline in Executive Function Performance on the Frontal Assessment Battery (FAB) at Week 11, primaryOutcomes measure: Change from Baseline in Executive Function Performance on the Colour Trails Test 2 at Week 11, eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 85 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Changi General Hospital, city: Singapore, country: Singapore, geoPoint lat: 1.28967, lon: 103.85007, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2021-01-27, uploadDate: 2024-04-15T09:12, filename: Prot_SAP_000.pdf, size: 384298, hasResults: False
protocolSection identificationModule nctId: NCT06380881, orgStudyIdInfo id: SHR-2017-102, briefTitle: PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Suzhou Suncadia Biopharmaceuticals Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: To evaluate the pharmacokinetic characteristics, pharmacodynamic characteristics, safety, tolerability and immunogenicity of SHR-2017 injection in patients with bone metastases, and to evaluate the efficacy of SHR-2017 injection in the treatment of skeletal-related event and cancer pain., conditionsModule conditions: Patients With Bone Metastases, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: SHR-2017, outcomesModule primaryOutcomes measure: The Pharmacokinetic parameters of SHR-2017 after administration, including Cmax, primaryOutcomes measure: The Pharmacokinetic parameters of SHR-2017 after administration, including Tmax, primaryOutcomes measure: The Pharmacokinetic parameters of SHR-2017 after administration, including AUC0-t, primaryOutcomes measure: The Pharmacokinetic parameters of SHR-2017 after administration, including AUC0-∞, primaryOutcomes measure: The Pharmacokinetic parameters of SHR-2017 after administration, including t1/2, primaryOutcomes measure: The Pharmacokinetic parameters of SHR-2017 after administration, including CL/F, primaryOutcomes measure: The pharmacodynamic parameter of SHR-2017 after administration include uNTX/uCr, primaryOutcomes measure: The pharmacodynamic parameter of SHR-2017 after administration include β-CTX, primaryOutcomes measure: The pharmacodynamic parameter of SHR-2017 after administration include BALP [Time, secondaryOutcomes measure: Change from baseline in worst pain/average pain at the designated bone metastasis pain site after dosing, secondaryOutcomes measure: Incidence of skeletal-related event, secondaryOutcomes measure: Average daily total opioids consumption, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Cancer Hospital, city: Beijing, state: Beijing, zip: 100142, country: China, contacts name: Huiping Li, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06380855, orgStudyIdInfo id: GIHSYSU-34, briefTitle: Flexible Colonoscope Assisted Hybrid Transanal Total Mesorectal Resection (taTME), statusModule overallStatus: RECRUITING, startDateStruct date: 2022-08-24, primaryCompletionDateStruct date: 2025-08-24, completionDateStruct date: 2025-08-24, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Sun Yat-sen University, class: OTHER, descriptionModule briefSummary: The investigators propose to use flexible endoscopy combined with transanal total mesorectal resection to further reduce anal injury., conditionsModule conditions: Rectal Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 5, type: ESTIMATED, armsInterventionsModule interventions name: Flexible colonoscope assisted hybrid transanal total mesorectal resection, outcomesModule primaryOutcomes measure: Success rate of operation, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of colorectal surgery, the Sixth Affiliated Hospital, Sun Yat-Sen University, status: RECRUITING, city: Guangzhou, state: Guangdong, zip: 510000, country: China, contacts name: Liang Kang, MD, PhD, role: CONTACT, phone: 008613602886833, email: eonkang@163.com, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06380842, orgStudyIdInfo id: 2023HX1970, briefTitle: Organ Dysfunction Change in Acute Necrotizing Pancreatitis Patients With Sepsis After Open Necrosectomy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2026-12-30, completionDateStruct date: 2026-12-30, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Chunling Jiang, class: OTHER, descriptionModule briefSummary: The purpose of this study is to characterize organ dysfunction change in acute necrotizing pancreatitis patients with sepsis after open necrosectomy., conditionsModule conditions: Necrotizing Pancreatitis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Necrotizing Pancreatitis patients' organ dysfunction progression, outcomesModule primaryOutcomes measure: Measure organ dysfunction change after open necrosectomy with respect to time, secondaryOutcomes measure: incidence of a composite of major complications, secondaryOutcomes measure: Incidence of ICU mortality, secondaryOutcomes measure: Incidence of hospital mortality, secondaryOutcomes measure: Incidence of 28-day mortality, secondaryOutcomes measure: Incidence of one year mortality, secondaryOutcomes measure: ICU length of hospital stay, secondaryOutcomes measure: Length of hospital stay, secondaryOutcomes measure: The pancreatic symptoms score, secondaryOutcomes measure: The levels of inflammatory factor CRP, secondaryOutcomes measure: The levels of inflammatory cytokines IL-6, secondaryOutcomes measure: The levels of inflammatory procalcitonin, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06380829, orgStudyIdInfo id: Adnan Menderes, briefTitle: Psychometric Properties of the Self-Care Assessment Scale for 3-6 Year Old Children With Cerebral Palsy-Parent Form, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-06-05, primaryCompletionDateStruct date: 2023-12-05, completionDateStruct date: 2024-02-10, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Aydin Adnan Menderes University, class: OTHER, descriptionModule briefSummary: This study is a methodological study to develop the self-care assessment scale-parent form of children with CP aged 3-6 years and test its validity and reliability.Q1. Is the Self-Care Assessment Scale for 3- to 6-year-old Children with CP a valid scale? Q2. Is the Self-Care Assessment Scale for 3- to 6-year-old Children with CP a reliable scale?, conditionsModule conditions: Cerebral Palsy, conditions: Self Care, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 127, type: ACTUAL, armsInterventionsModule interventions name: Questionnaire, outcomesModule primaryOutcomes measure: To asses Turkish validity and reliability of Self-Care Assessment Scale for Children with CP aged 3-6 years, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 6 Years, stdAges: CHILD, contactsLocationsModule locations facility: Bircan Kahraman Berberoğlu, city: Aydın, zip: 0900, country: Turkey, geoPoint lat: 37.84501, lon: 27.83963, hasResults: False
protocolSection identificationModule nctId: NCT06380790, orgStudyIdInfo id: 8423, briefTitle: Effect of Laser-aided Csf on the Rate of Leveling and Alignment of Mandibular Anterior Crowding, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-01, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: To test the effect of laser-aided circumferential supracrestal fiberotomy on the rate of leveling and alignment, conditionsModule conditions: Orthodontics, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 26, type: ESTIMATED, armsInterventionsModule interventions name: Laser-aided csf, interventions name: placebo laser-aided csf, outcomesModule primaryOutcomes measure: Rate of tooth movement, secondaryOutcomes measure: Pain level, secondaryOutcomes measure: Periodontal health, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 25 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of dentistry cairo university, status: RECRUITING, city: Cairo, country: Egypt, contacts name: Cairo University, role: CONTACT, phone: 0223638755, email: ortho@dentistry.cu.edu.eg, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06380777, orgStudyIdInfo id: DDT system for sarcopenia, briefTitle: Establishment and Application of Digital Diagnosis and Treatment System for Sarcopenia, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2028-12-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Peking Union Medical College Hospital, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to establish a digital diagnosis and treatment system for sarcopenia, integrating research outcomes into a unified approach encompassing a digital vaccine (early warning screening model), digital drug (intervention model associated with pathogenesis), and digital rehabilitation (preventive system combining early warning and treatment). This aims to create a digital visual tertiary prevention network for sarcopenia.Research aims:Evaluate the effectiveness of the digital vaccine through a cross-sectional epidemiological survey.Establish a specialized cohort for sarcopenia through a longitudinal investigation, implementing the digital drug and digital rehabilitation interventions.Participants will:Engage in screening and assessment based on inclusion and exclusion criteria.Be monitored longitudinally, with tailored interventions for those with muscle atrophy and regular follow-ups for at-risk individuals.Key outcomes will focus on sarcopenia indicators, serum biomarkers, and clinical endpoints such as fracture rates, weakness classification, and quality of life., conditionsModule conditions: Sarcopenia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 10000, type: ESTIMATED, outcomesModule primaryOutcomes measure: Appendicular skeletal muscle mass index, secondaryOutcomes measure: Hand grip strength, secondaryOutcomes measure: Gait speed, otherOutcomes measure: Concentration of insulin, otherOutcomes measure: Concentration of adiponectin, otherOutcomes measure: Concentration of leptin, otherOutcomes measure: Concentration of insulin like growth factor -1(IGF-1), otherOutcomes measure: Concentration of interleukin 18 (IL-18), otherOutcomes measure: Concentration of tumor necrosis factor - α (TNF-α), otherOutcomes measure: Concentration of TNF-like weak inducer of apoptosis (TWEAK), otherOutcomes measure: Concentration of fibroblast growth factor -19 (FGF-19), otherOutcomes measure: Concentration of myostatin, otherOutcomes measure: Concentration of chemoattractant protein-1 (MCP-1), otherOutcomes measure: Concentration of activin, eligibilityModule sex: ALL, minimumAge: 45 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking Union Medical College Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100730, country: China, contacts name: Kang Yu, MD, role: CONTACT, phone: +86 010-69155550, email: yuk1997@sina.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06380764, orgStudyIdInfo id: RC.11.3.2024, briefTitle: Greater Occipital Nerve Block Value in Management of Postdural Puncture Headache, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-03-02, primaryCompletionDateStruct date: 2023-07-25, completionDateStruct date: 2023-12-01, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Benha University, class: OTHER, descriptionModule briefSummary: Neuraxial techniques are well tolerated and effective options for labor analgesia and anesthesia for caesarean section, and may protect high risk women against severe maternal morbidity. However, neuraxial techniques still have drawbacks especially postdural puncture headache (PDPH) and may be associated with chronic headache, back pain and postnatal depression. PDPH is a relatively common acute complication of neuraxial techniques that was traditionally considered benign and self-limiting, but it significantly impacts patients' general health and quality of life.Greater Occipital Nerve (GON) originates from C2-3 segments and through its muscular relations it is divided as proximal and distal parts; the most proximal part lies between obliquus capitis inferior and semispinalis and then passes through the semispinalis to pierce the trapezius muscle. In distal region of trapezius fascia, the GON is crossed by the occipital artery and exits the trapezius fascia into the nuchal line about 5-cm lateral to midline. Functionally, GON provides motor supplies to the muscles while passing through it and its main sensory supply is in the occipital region., conditionsModule conditions: Postdural Puncture Headache, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 152, type: ACTUAL, armsInterventionsModule interventions name: Greater Occipital Nerve Block, interventions name: Bilateral suboccipital intramuscular injection, interventions name: Epidural Blood Patch, interventions name: Normal Saline 10 mL Injection, interventions name: Lidocaine 2% Injectable Solution, outcomesModule primaryOutcomes measure: The extent of reduction of consumed analgesia, eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Benha university, city: Banhā, state: El Qalyoubia, zip: 13511, country: Egypt, geoPoint lat: 30.45906, lon: 31.17858, hasResults: False
protocolSection identificationModule nctId: NCT06380725, orgStudyIdInfo id: jshim8zay6vd, briefTitle: The Treatment of High Intensity Transcranial Current Stimulation for Alzheimer's Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-08, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Anhui Provincial Hospital, class: OTHER_GOV, descriptionModule briefSummary: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive dysfunction and behavioral impairment. It is currently the most common type of dementia in the old age. At present, the clinical treatment of Alzheimer's disease is expensive and has side effects, so it is very important to explore new methods of treatment for AD. Investigators designed a prospective, randomized, double-blinded and placebo-controlled trial to investigate the effect of transcranial alternating current stimulation (tACS) on cognitive function in AD patients and to assess the biological effectiveness of the treatment., conditionsModule conditions: Alzheimer's Disease, conditions: Mild Cognitive Impairment, conditions: Dementia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Investigators designed a randomized double-blinded placebo-controlled trial by randomly dividing subjects into two groups: one is the treatment group and the other is the placebo group., primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: Investigators designed a double-blinded trial in which neither the investigator nor the subjects know whether they will be received the treatment or a placebo., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Transcranial alternating current stimulation(real stimulation), interventions name: Transcranial alternating current stimulation(sham stimulation), outcomesModule primaryOutcomes measure: Cognitive appraisal, primaryOutcomes measure: Global Cognitive appraisal, primaryOutcomes measure: Psychobehavioral assessment, secondaryOutcomes measure: Near-infrared spectroscopy, secondaryOutcomes measure: Event related potential measurement, secondaryOutcomes measure: Peripheral blood biomarkers, secondaryOutcomes measure: Magnetic Resonance Imaging, secondaryOutcomes measure: Incidence of side effects, eligibilityModule sex: ALL, minimumAge: 45 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06380699, orgStudyIdInfo id: HJG-CZQH-QHRD106-I, briefTitle: Study to Assess PK, Safety and Tolerability in Healthy Subjects, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-03-16, primaryCompletionDateStruct date: 2023-11-16, completionDateStruct date: 2023-12-25, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Changzhou Qianhong Bio-pharma Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of QHRD106 in Chinese healthy subjects with single and multiple doses., conditionsModule conditions: Acute Ischemic Stroke, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 56, type: ACTUAL, armsInterventionsModule interventions name: QHRD106 Injection, interventions name: Yurekline, interventions name: placebo, outcomesModule primaryOutcomes measure: Safety as assessed by incidence, severity, and causality of adverse events, primaryOutcomes measure: Plasma measurements of QHRD106, primaryOutcomes measure: Concentration of bradykinin in plasma, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Nanjing Drum Tower Hospital, city: Nanjing, state: Jiangsu, zip: 210008, country: China, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06380686, orgStudyIdInfo id: AIO-KHT-0322/ass, briefTitle: Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome, acronym: HEAT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2029-05, completionDateStruct date: 2030-05, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: AIO-Studien-gGmbH, class: OTHER, collaborators name: Merck Sharp & Dohme LLC, descriptionModule briefSummary: Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent/metastatic head and neck tumor patients., conditionsModule conditions: Squamous Cell Carcinoma of the Oral Cavity, conditions: Squamous Cell Carcinoma of the Oropharynx, conditions: Squamous Cell Carcinoma of the Hypopharynx, conditions: Squamous Cell Carcinoma of the Larynx, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: data collection, outcomesModule primaryOutcomes measure: Sociodemographic factors, primaryOutcomes measure: Treatments, primaryOutcomes measure: Response rates, primaryOutcomes measure: Treatment decision, primaryOutcomes measure: Progression-free survival, primaryOutcomes measure: Time-to-treatment-failure, primaryOutcomes measure: Overall survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Universitätsklinikum Essen, city: Essen, zip: 45147, country: Germany, contacts name: Victor Grünwald, Prof. Dr., role: CONTACT, phone: +49 201 723 85584, email: viktor.gruenwald@uk-essen.de, geoPoint lat: 51.45657, lon: 7.01228, hasResults: False